1. Home
  2. KREF vs ALLO Comparison

KREF vs ALLO Comparison

Compare KREF & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Real Estate Finance Trust Inc.

KREF

KKR Real Estate Finance Trust Inc.

HOLD

Current Price

$6.11

Market Cap

499.0M

Sector

Real Estate

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.68

Market Cap

597.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KREF
ALLO
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
499.0M
597.7M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
KREF
ALLO
Price
$6.11
$1.68
Analyst Decision
Hold
Strong Buy
Analyst Count
6
15
Target Price
$7.88
$8.35
AVG Volume (30 Days)
537.9K
4.8M
Earning Date
04-22-2026
05-07-2026
Dividend Yield
6.49%
N/A
EPS Growth
N/A
34.09
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$545.92
N/A
Revenue Next Year
N/A
$142,416.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$1.04
52 Week High
$9.53
$4.46

Technical Indicators

Market Signals
Indicator
KREF
ALLO
Relative Strength Index (RSI) 25.62 N/A
Support Level $6.15 N/A
Resistance Level $6.64 N/A
Average True Range (ATR) 0.18 0.00
MACD -0.09 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
KREF
ALLO

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Share on Social Networks: